Cellebration Life Sciences, Inc. has teamed with the Global Institute of Stem Cell Therapy and Research (GIOSTAR) to provide world-class research in the development of a curative treatment for Type 2 Diabetes.

Headed by Anand Srivastava, PhD, considered by many as the “Father of Stem Cell Research”, Cellebration currently has underway a U.S. Food and Drug Administration (FDA) Pre-Investigational Clinical Trial application. Results from a preliminary clinical trial conducted in India indicate an up to 75% reduction in insulin usage in clinical trial patients. The U.S. Department of Health and Human Services estimates that more than 41 million Americans have or are pre-disposed to Type 2 Diabetes. This represents a market size for treatments of more than $300 billion annually.

Globally, the World Health Organization estimates that close to 500 million people suffer from this disease representing a market size for treatments of more than $800 billion per year. The success of Cellebration’s Clinical Trial is expected to significantly alter the worldwide strategy for the treatment of this devastating disease and is anticipated to accrue significant benefits to Cellebration’s shareholders.

In addition, to further enhance shareholder value, Cellebration Life Sciences owns a fully licensed and operational state-of-the-art stem cell rejuvenation and regeneration wellness center in San Jose, Costa Rica to serve patient needs in both North and South America. (cellebrationwellness.com) One-on-one patient services are provided at this center to enhance the quality of life for those suffering from autoimmune diseases and orthopedic injuries.

Cellebration Life Sciences, Inc. has teamed with the Global Institute of Stem Cell Therapy and Research (GIOSTAR) to provide world-class research and treatments for life-threatening autoimmune diseases and orthopedic injuries.

Working closely with the scientists at GIOSTAR, Cellebration’s research team is focused on finding cures for diabetes and crippling arthritis.

Cellebration currently has underway an FDA Clinical Trial application the aim of which is to develop a curative treatment for Type 2 Diabetes. We are also conducting further research to advance efforts to find permanent curative treatments for arthritis and other autoimmune diseases.

In addition, a state-of-the-art rejuvenation and regeneration wellness center is being developed in Costa Rica to serve patient needs in both North and South America.